Clinical Trials Logo

Advanced Solid Tumor clinical trials

View clinical trials related to Advanced Solid Tumor.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06228846 Active, not recruiting - Clinical trials for Advanced Solid Tumor

An Phase I Study of YY001 in Patients With Advanced Solid Tumors

Start date: July 14, 2022
Phase: Phase 1
Study type: Interventional

The safety and tolerability of YY001 in the treatment of patients with advanced solid tumors were evaluated, and the possible dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) or recommended phase II clinical dose (RP2D) were observed.

NCT ID: NCT05990920 Active, not recruiting - Solid Tumor Clinical Trials

Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy

Start date: August 23, 2023
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to test SNK02 in participants with pathologically confirmed cancer that is refractory to conventional therapy. The main questions it aims to answer are: - Is SNK02 safety and tolerable when administered weekly as an intravenous infusion - What is the maximum dose that is tolerated of SNK02 Participants will be administered SNK02 weekly for 8 weeks and undergo medical evaluation to provide initial clinical safety data for the treatment of cancer with allogeneic NK cells as a monotherapy treatment.

NCT ID: NCT05971862 Active, not recruiting - Clinical trials for Advanced Solid Tumor

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SKI-G-801 in Patients With Advanced Solid Tumors

Start date: January 25, 2022
Phase: Phase 1
Study type: Interventional

This is a phase I study intended to determine the MTD and RP2D of SKI-G-801 monotherapy by assessing the safety and tolerability including dose-limiting toxicity (DLT) at various dose levels and to explore the efficacy and PK in patients with advanced solid tumors.

NCT ID: NCT05801094 Active, not recruiting - Clinical trials for Advanced Solid Tumor

A Phase I Study of QL1604 for Advanced Solid Tumors

Start date: July 20, 2020
Phase: Phase 1
Study type: Interventional

In this study, patients with advance solid tumors will be treated with QL1604 monotherapy.

NCT ID: NCT05764915 Active, not recruiting - Clinical trials for Advanced Solid Tumor

A Phase I Study of RGT-264 in Subjects With Advanced Solid Tumors

Start date: February 15, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase 1 dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of RGT-264 as monotherapy in subjects with advanced solid tumors.

NCT ID: NCT05757492 Active, not recruiting - Clinical trials for Non-Small Cell Lung Cancer

Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Start date: April 26, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This phase 1 open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of CHS-006 in combination with toripalimab in 2 phases. Phase 1 (Dose Optimization phase) will explore 2 different dose combinations in participants with advanced/metastatic solid tumors (except pancreatic) and Phase 2 (Indication-specific Expansion phase) will use one selected dose in specific tumor types (non-small cell lung cancer-non squamous [NSCLC-NS] and Hepatocellular carcinoma [HCC])

NCT ID: NCT05631327 Active, not recruiting - Clinical trials for Advanced Solid Tumor

A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors

Start date: December 19, 2022
Phase: Phase 1
Study type: Interventional

This study will assess the safety and efficacy of JZP341 in participants with advanced or metastatic solid tumors.

NCT ID: NCT05621486 Active, not recruiting - Clinical trials for Advanced Solid Tumor

A Clinical Study to Evaluate B4T2-001 CAR T Cells in the Treatment of Advanced Solid Tumors

Start date: September 14, 2022
Phase: Phase 1
Study type: Interventional

This is a first in human (FIH), open-label, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of B4T2-001 Autologous CAR T cells in subjects with advanced solid tumors including but not limited to advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma, advanced pancreatic cancer, advanced non-small cell lung cancer (NSCLC), colorectal cancers (CRC) and metastatic breast cancer that tests positive for BT-001 target antigen according to Immunohistochemistry (IHC).

NCT ID: NCT05594875 Active, not recruiting - Clinical trials for Advanced Solid Tumor

A Trial of SHR-A1921 for Injection in Subjects With Advanced Solid Tumors

Start date: December 1, 2022
Phase: Phase 1
Study type: Interventional

The study is being conducted to evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of SHR-1921.

NCT ID: NCT05414136 Active, not recruiting - Clinical trials for Advanced Solid Tumor

Evaluating the Safety, Tolerability, and Pharmacokinetics of BAT1006

Start date: February 10, 2022
Phase: Phase 1
Study type: Interventional

Primary objectives: To evaluate the safety and tolerability of BAT1006 in patients with advanced her2-positive solid tumors. To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT). Secondary objectives: 1) To evaluate the pharmacokinetic characteristics of BAT1006 after single and multiple dosing; 2) To study the immunogenicity of BAT1006; 3) Preliminary evaluation of anti-tumor efficacy of BAT1006.